Overview of Монкаста

Property	Description
Active ingredient	Montelukast sodium
Form	Film-coated tablet, chewable tablet, oral granules
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
General purpose	Control of inflammation and constriction in airways
Origin	Synthetic, non-steroidal compound

What Type of Medicine is Монкаста (Montelukast)?

Монкаста is a prescription-only pharmaceutical agent whose active ingredient is Montelukast sodium, systematically classified as a Leukotriene Receptor Antagonist (LTRA). This medication belongs to the leukotriene modifiers class, characterized by its mechanism as a highly selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist. Montelukast is a synthetic and non-steroidal compound, providing a distinct functional profile compared to corticosteroid treatments. Montelukast is primarily used to block chemicals that cause swelling. The development of Montelukast sodium as a specific LTRA is characterized by the compound's ability to halt the inflammatory cascade at a molecular level.

Understanding the General Purpose and Form

The general purpose of Монкаста is to provide systemic control over inflammatory processes by achieving targeted blockade of leukotriene activity, which helps to mitigate airway tightening and swelling. This anti-inflammatory consequence is the foundation of its general therapeutic benefit in scenarios requiring maintenance control of respiratory irritation. Montelukast's action on the leukotriene pathway is established for reducing airway inflammation. For patient convenience and systemic delivery, the drug is formulated exclusively for oral administration, offering patient flexibility through three distinct dosage forms: the standard film-coated tablet, the patient-friendly chewable tablet, and the oral granule preparation. This breadth of options ensures the medicine can be integrated easily across the target audience, including both adults and pediatric patients.

Regulatory References

MedlinePlus: Montelukast Drug Information

What side effects are possible with Монкаста?

Adverse Reactions and Safety Profile

The safety profile for this medicine is based on comprehensive data from clinical trials and post-marketing surveillance, classified by major governmental health agencies.

Serious Adverse Reactions

Regulatory agencies, including the FDA and EMA, have highlighted the risk of serious neuropsychiatric events. These include, but are not limited to, agitation, aggression, abnormal dreams, depression, hallucinations, insomnia, irritability, restlessness, and suicidal thoughts and behaviour. Patients and caregivers are advised to be alert for these changes and seek immediate medical attention if they occur.

Another serious consideration is Systemic Eosinophilia with Vasculitis (consistent with Churg-Strauss Syndrome), which has been reported, often in association with the reduction of oral corticosteroid therapy.

Frequency-Classified Side Effects

Adverse reactions are grouped by the likelihood of occurrence:

Classification	Example Reactions (System Organ Class)
Very Common (ge 1/10)	Upper respiratory infection
Common (ge 1/100 to <1/10)	Headache, Abdominal pain
Uncommon (ge 1/1,000 to <1/100)	Abnormal dreams/nightmares, anxiety, depression, seizures, rash, dry mouth, elevated liver enzymes (ALT/AST)
Rare/Very Rare	Hypersensitivity (anaphylaxis), increased bleeding tendency, hepatitis, severe skin reactions (e.g., Stevens-Johnson syndrome)

Safety Restrictions and Limitations

Acute Asthma: This medicine is not indicated for the reversal of bronchospasm in acute asthma attacks.
Corticosteroid Substitution: Treatment should not be abruptly substituted for inhaled or oral corticosteroids.
Population Notes: Safety data in pediatric patients (2–14 years old) are generally similar to adults. The same critical warnings, particularly regarding neuropsychiatric events, apply to all age groups.

Regulatory Safety Structure

The official safety documents structure the medicine’s risk profile by placing a prominent emphasis on the potential for serious neuropsychiatric events, which defines a key safety constraint. This formal structure ensures that while the most frequent side effects are minor (e.g., headache), the significant risks (like suicidality or Churg-Strauss Syndrome) are explicitly communicated for informed awareness.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Montelukast (Монкаста) based on reported clinical manifestations and mandated emergency response procedures. Overdose cases have been reported in both adults and children following acute ingestion of high doses. The adverse experiences observed are generally consistent with the drug's known safety profile. The officially documented symptoms reported in these cases include effects on the gastrointestinal system, specifically abdominal pain, vomiting, and thirst. Central nervous system manifestations have also been reported, including somnolence (drowsiness), headache, and psychomotor hyperactivity.

Urgent medical assistance must be sought immediately if an overdose is suspected. This action is mandated because no specific information is available on the treatment of overdosage, indicating that no specific antidote is known for Montelukast. Consequently, the management approach mandated by regulatory authorities is the implementation of usual supportive measures. These emergency procedures require employing clinical monitoring and instituting supportive therapy as necessary. A key initial action is the removal of any unabsorbed material from the gastrointestinal tract. The official prescribing information also notes a specific constraint for practitioners: it is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.

Therapeutic Uses of Монкаста

Montelukast is relevant for easing symptoms in conditions characterized by symptoms related to inflammatory or irritative states. It is applied across therapeutic domains including the long-term symptom management of persistent asthma symptoms, relief of seasonal and perennial allergic rhinitis, and prophylaxis against exercise-triggered breathing difficulty.

Understanding the Therapeutic Benefit

This medication is generally used as a daily treatment for patients who experience chronic symptoms, which may include wheezing, chest tightness, coughing, and nasal congestion. It supports the long-term management of chronic inflammation, which contributes to maintaining functional stability and helps patients cope more steadily with symptom fluctuations. It is relevant for easing discomfort associated with allergic reactions and for preventing airway narrowing associated with physical exertion.

“It plays a role in managing symptoms associated with acute or episodic changes, which may assist with maintaining functional stability.”

Quick Fact: Relief for Upper and Lower Respiratory Symptoms

Therapeutic Indications at a Glance

Монкаста is relevant for easing symptoms in three key clinical areas: chronic asthma, seasonal allergic rhinitis, and perennial allergic rhinitis. It also plays a supportive role in preventing exercise-induced breathing difficulties, assisting with managing symptoms that create noticeable physiological strain.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

Eligibility Category	Status as Stated in Regulatory Documents
Contraindications	Use is absolutely contraindicated in patients with known hypersensitivity to Montelukast or any component. The medicine is not suitable for acute asthma attacks or status asthmaticus.
Age-Group Rules	Eligibility is established at different minimum ages: ge 6 months (Perennial Allergic Rhinitis), ge 12 months (Asthma), ge 2 years (Seasonal Allergic Rhinitis), and ge 6 years (EIB Prophylaxis). Safety is not established for populations below these thresholds. Older adults (ge 65) require no dose adjustment.
Organ/Comorbidity	No adjustment is required for renal or mild-to-moderate hepatic impairment. Use in severe hepatic impairment is unassessed. Caution is advised for patients with a history of neuropsychiatric events or certain hereditary intolerances (e.g., lactose or PKU for chewable tablets).
Pregnancy/Lactation	Use is permitted only if considered clearly essential (EMA/SmPC).

The official eligibility profile is structured around these absolute exclusions and conditional parameters. Eligibility is dependent on meeting specific minimum age thresholds for the treated condition and is subject to restrictions for patients with certain comorbidities or excipient intolerances. Use for allergic rhinitis is often reserved for patients who have an inadequate response to alternative therapies.

What should I know about interactions with other medicines?

The official product labeling for montelukast specifies several types of interactions, mainly relating to the drug's metabolism and co-administration with other respiratory treatments.

Interacting Product Category	Specific Examples Listed	Practical Constraint/Implication
Potent Enzyme Inducers	Phenobarbital, Phenytoin, Rifampicin	These drugs can decrease montelukast's systemic exposure (AUC) by up to 40% (e.g., with phenobarbital), potentially reducing its effect. Careful monitoring is advised, particularly in children.
Enzyme Inhibitors	Gemfibrozil (inhibits CYP2C8, 2C9)	Can significantly increase montelukast's systemic exposure (up to 4.4-fold increase in AUC reported), requiring clinical caution and monitoring.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Aspirin, other NSAIDs	Patients with known aspirin sensitivity should continue to avoid aspirin and other NSAIDs while taking montelukast.
Inhaled or Oral Corticosteroids	N/A	Montelukast should not be abruptly substituted for inhaled or oral corticosteroids; reduction of corticosteroid dose must be gradual and supervised by a physician.
Products Containing Montelukast	N/A	Should not be used concomitantly with any other product containing montelukast as the active ingredient.

In clinical studies, co-administration with other commonly used drugs like theophylline, prednisone, digoxin, and warfarin did not result in clinically significant changes to the pharmacokinetics of montelukast. The drug is primarily metabolized by CYP3A4, 2C8, and 2C9 enzymes, which informs the noted interactions with strong inducers and inhibitors of these pathways.

Mechanism of Action

How Монкаста Works

Монкаста (Montelukast) operates through the establishment of a targeted blockade of the Cysteinyl Leukotriene Type 1 Receptor ( CysLT1), which serves as its sole, high-affinity molecular target. This interaction is a selective and competitive antagonism that prevents the natural binding and subsequent cellular signaling of the endogenous cysteinyl leukotrienes ( LTD4, LTC4, LTE4), thereby interrupting a key segment of the Arachidonic Acid Cascade.

Inhibition of CysLT1 receptor activation directly modulates two critical physiological outcomes. The mechanism prevents the signaling cascade that causes airway smooth muscle cells to contract (anti-bronchoconstriction) and limits the cellular activity that leads to increased vascular permeability and fluid leakage. This results in the inhibition of the physiological development of airway edema in the bronchial lining. This foundational mechanism produces the long-term modulation of CysLT-driven physiological hyper-responsiveness.

The drug’s role is defined as a sustained pathway modulator and is not physiologically designed for immediate action. Consequently, it lacks the speed or magnitude required to rapidly reverse established severe muscle contraction characteristic of an acute event.

Dosage and Administration Information

Montelukast is administered exclusively via the oral route, utilizing fixed, age-specific doses across its three primary formulations: film-coated tablets, chewable tablets, and oral granules. The administration follows a mandatory once-daily regimen.

The standard daily dose for adults and adolescents 15 years and older is 10 mg. For children, the dose is fixed according to age group: 5 mg for those 6 to 14 years, and 4 mg for children 6 months to 5 years. The 10 mg dose represents the maximum recommended daily intake. This medicine is generally intended for long-term maintenance and the dose is not subject to routine upward or downward titration.

The dose for chronic management is typically taken in the evening, independent of meals. When Montelukast is used prophylactically for exercise-induced breathing difficulty, the dose must be taken at least two hours prior to the activity, and an additional dose should not be taken if the regular daily dose has been administered within 24 hours.

Specific preparation rules apply to the 4 mg oral granules: they must be administered within 15 minutes of opening the sachet, and while they can be mixed with a small amount of soft food (e.g., applesauce), they should not be dissolved in any liquid. If a daily dose is missed, the next dose should be taken at the scheduled time; a compensating double dose is not permitted. Dosage adjustment is not required for older adults or in cases of mild-to-moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Монкаста (Montelukast)

This overview summarizes the type of research that has been conducted for Montelukast and what studies have observed, based on reports from governmental and scientific sources. This information is intended to contextualize the agent and is not clinical advice.

Evidence for Long-Term Management of Persistent Asthma

Research on this agent was primarily conducted using double-blind Randomized Controlled Trials (RCTs). These studies were used to compare the agent against an inactive pill (placebo) or against other recognized forms of management. Researchers monitored key outcomes monitoring physiological strain or stress, including lung function tests (such as the volume of air expelled in the first second of a forced breath), how often rescue medication was used, and the frequency of asthma exacerbations in observed populations.

Trials reported patterns in lung function measurements and outcomes related to functional status in cohorts with mild to moderate persistent asthma. Research examined patterns related to changes in the frequency of asthma symptoms over time. When studies explored how symptoms evolved in patients compared directly to other management options, findings were mixed regarding changes in certain inflammatory markers and control of nighttime symptoms.

Evidence for Relief of Allergic Rhinitis Symptoms

The research on the use of this agent for allergic rhinitis symptoms was studied for both seasonal and perennial conditions. The research setting mostly involved short-term Randomized Controlled Trials (RCTs). These studies typically examined outcomes related to physical discomfort by measuring changes in nasal symptom scores (including congestion, sneezing, and runny nose) and patient-reported outcomes describing perceived discomfort over periods ranging from a few weeks to a few months.

Regulatory reviews have indicated that this agent has been positioned for study in cohorts that have demonstrated an inadequate response to or intolerance of alternative allergy medications. The evidence quality varies across studies, and there is noted inconsistency when comparing the agent to alternative management forms studied in the research.

Evidence for Prevention of Exercise-Induced Bronchoconstriction (EIB)

Research exploring the prevention of EIB was evaluated in specific controlled cross-over trials. The main research focus was studied for outcomes related to physiological strain or stress by measuring the maximum percent fall in FEV1 (a key lung function measure) after a standardized exercise challenge. Trials reported data show patterns related to a protective effect that was measurable up to 24 hours after a single dose. Chronic treatment studies monitored responses over defined time intervals (several weeks) and reported that the protective observation was maintained with continuous daily administration.

What is Still Uncertain About the Research Base

The scientific evidence highlights areas where data are still emerging or where the research remains limited. Findings were mixed in head-to-head comparative research against other standard management approaches, particularly regarding some measures of inflammation and nighttime symptoms. Data for certain groups, including specific patient cohorts with comorbidities, remain insufficient to draw broad conclusions. These limitations mean that the research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References Montelukast: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Монкаста (FAQ)

Q: How quickly does Монкаста start working?

Official clinical studies have observed that improvement in certain physiological measures related to asthma has been observed in some studies to begin within one day after starting this medicine. However, the agent is classified as a chronic controller, meaning it is intended for sustained management and is not designed to provide immediate relief or reverse acute, severe symptoms.

Q: Are there any food or drinks that should be avoided when taking Монкаста?

According to the official product information, this medicine can be taken with or without food. Regulatory documents state that there are no specific foods or drinks that are required to be strictly avoided. Preparation instructions for the oral granules, however, specify which soft foods they can be mixed with.

Q: Does alcohol interact negatively with Монкаста?

Official prescribing information generally does not list a direct interaction between this medicine and alcohol. Nevertheless, post-marketing reports have noted the possibility of adverse liver reactions. Liver problems have been reported, and patients with underlying risk factors should discuss these concerns with a healthcare provider.

Q: Can Монкаста be crushed or split?

The medicine is available in three forms: oral granules, chewable tablets, and film-coated tablets. Regulatory documents provide explicit handling rules for oral granules and chewable tablets, but do not contain instructions for crushing or splitting the film-coated tablets.

Q: If I miss a dose of Монкаста, what is the advice?

Official regulatory guidance on dosing states that if a daily dose is missed, the next dose should be taken at its regularly scheduled time. The advice provided in product information is that a compensating double dose is not permitted.

Q: Can Монкаста affect your sleep?

Official adverse reaction data includes reports of sleep disturbances. These have included reactions such as insomnia (difficulty sleeping), abnormal dreams or nightmares, and, rarely, sleepwalking. Official guidance informs patients and caregivers about these potential effects.

Q: Is there a link between Монкаста and mood changes or behavior?

Yes, regulatory bodies require prominent warnings regarding the potential for serious neuropsychiatric events. These reported changes include mood and behavior alterations such as aggression, agitation, depression, hallucinations, irritability, restlessness, and suicidal thoughts or behavior. Official guidance informs patients and caregivers about these potential effects.

Q: Does Монкаста help with nasal congestion?

Research examining the medicine's use for allergic rhinitis symptoms has been studied for both seasonal and perennial conditions. These studies specifically measured changes in patient-reported nasal symptom scores, which include congestion, sneezing, and runny nose.

Q: Are headaches a common side effect of Монкаста?

Yes, regulatory documents classify headache as a common side effect of this medicine. This means that, based on clinical trial data, the effect has been reported in up to 1 in 10 patients.

Q: How can I tell if Монкаста is working for my condition?

Studies indicate effectiveness may be monitored through objective and subjective outcomes, such as a reduction in rescue medication use or improvements in lung function tests. However, this medicine is a long-term controller, and its full effect may not be apparent immediately.

Q: Are there any specific liver concerns mentioned with Монкаста use?

Official safety data mentions specific liver-related concerns. These include reports of elevated liver enzymes (ALT and AST) and, in rare instances, reports of hepatitis (inflammation of the liver). Caution is advised for patients with existing liver issues.

Q: Why is the drug name Монкаста (Montelukast)?

The name of the active ingredient, montelukast, is commonly understood to be related to the city of Montreal, where the drug was developed. The US National Library of Medicine confirms that Montelukast is primarily used to block chemicals that cause swelling.

Q: Does Монкаста help with coughing?

While not a primary indication, research trials have been conducted to evaluate the effects of this medicine on cough-related outcomes. These studies have specifically examined the impact of the agent on cough reflex sensitivity and cough scores in cohorts diagnosed with cough-variant asthma.

Q: Is there any research on Монкаста for skin conditions?

Clinical trial registries show that research has been conducted to investigate the potential efficacy of this agent for certain skin conditions. One area of study has been the evaluation of its use for atopic dermatitis when triggered by specific food allergens.

Q: Do you have to take Монкаста for a set amount of time?

This medicine is designated for long-term maintenance treatment rather than short-term use. The specific duration of therapy must be determined by the prescriber and is based on the patient's condition and the official indication being treated.

Q: Why do some people take Монкаста in the evening?

For the chronic management of asthma, the official prescribing information directs that the medicine be taken once daily in the evening. For other medical indications, the timing of the dose may be adjusted based on the specific clinical circumstance.

Q: Are there any studies looking into new uses for Монкаста?

Regulatory information and clinical trial registries show that studies continue to be conducted on the medicine. Research areas often include new aspects of its use, such as extended safety in pediatric populations and the evaluation of its effects on various symptoms.

Q: Can I take Монкаста with vitamins or supplements?

Due to the absence of specific regulatory data, there is insufficient information to confirm the safety of taking complementary medicines or supplements concurrently with this agent.

Q: What are the signs of a serious side effect from Монкаста?

Patients and caregivers are advised by regulatory bodies to be highly alert for any changes in mood or behavior, particularly the onset of new neuropsychiatric symptoms. The regulatory guidance advises seeking medical advice immediately should these symptoms occur.

Q: Can Монкаста be used by children?

Yes, this medicine is suitable for pediatric patients, with eligibility established from a minimum age of six months for specific indications. The age eligibility varies depending on the medical condition being treated.

Q: How long can a person safely take Монкаста?

The medicine is classified as a long-term maintenance treatment, and clinical studies have followed patients for extended periods. Regulatory safety data have included clinical studies that documented treatment duration for up to 52 weeks.

Q: What is still uncertain about the research base?

Scientific evidence highlights several areas where data remain limited or are still emerging. These limitations include mixed findings in head-to-head comparative research against other standard management approaches and insufficient data for specific patient groups with multiple underlying conditions.

How should Монкаста be stored and disposed of?

The storage and disposal of Montelukast (Монкаста) must strictly adhere to regulatory guidelines to ensure stability and safety.

Official Storage Conditions

Montelukast must be stored below 25 C and kept in the original package to maintain the necessary protection from light and moisture. Storage rules also mandate that the product be kept out of the sight and reach of children at all times.

Stability and Handling

The medicine is sensitive to environmental factors. For the oral granules, if mixed with food, the full dose must be administered within 15 minutes, and any unused portion must be immediately discarded. Products supplied in multi-dose containers may have a strict in-use shelf life of 30 days after opening.

Disposal Requirements

Any unused or expired Montelukast medicinal product must be disposed of in accordance with local regulatory requirements for pharmaceutical waste, and discharge into drains or water courses should be avoided.

Монкаста